Literature DB >> 3559811

Inositol supplementation in respiratory distress syndrome: relationship between serum concentration, renal excretion, and lung effluent phospholipids.

M Hallman, P Arjomaa, K Hoppu.   

Abstract

Inositol or placebo was given to 48 small preterm infants with respiratory distress syndrome (mean birth weight 1365 g, gestational age 30.1 weeks) between 48 hours and 10 days of age. The dose of inositol, 40 mg/kg every 6 hours, was at least as high as amounts received in full preterm human milk feedings. Serum inositol concentration increased between days 2 and 3 from a mean of 566 mumol/L to 823 mumol/L in the infants given supplement and fell from 451 mumol/L to 292 mumol/L in the controls. On day 16, serum inositol values remained higher in the infants given supplement than in those given placebo (mean 334 mumol/L vs 146 mumol/L, P = 0.014). The infants who developed bronchopulmonary dysplasia had significantly higher renal inositol clearance, lower inositol intake, and lower serum inositol concentrations. Inositol supplementation increased the saturated phosphatidylcholine/sphingomyelin ratio in tracheal aspirates. According to these results, supplementation with inositol in preterm infants leads to a rise in serum inositol concentration and improvement in the surfactant phospholipids. Inositol deserves further study as a dietary supplement for immature preterm infants who do not receive full human milk feeds.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3559811     DOI: 10.1016/s0022-3476(87)80561-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  11 in total

Review 1.  Current perspectives on the drug treatment of neonatal respiratory distress syndrome.

Authors:  D G Sweet; H L Halliday
Journal:  Paediatr Drugs       Date:  1999 Jan-Mar       Impact factor: 3.022

Review 2.  Prevention and treatment of bronchopulmonary dysplasia: contemporary status and future outlook.

Authors:  Laura Cerny; John S Torday; Virender K Rehan
Journal:  Lung       Date:  2008-01-30       Impact factor: 2.584

Review 3.  Retinopathy of prematurity: a review of risk factors and their clinical significance.

Authors:  Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang
Journal:  Surv Ophthalmol       Date:  2018-04-19       Impact factor: 6.048

4.  Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks' Gestational Age: A Randomized Clinical Trial.

Authors:  Dale L Phelps; Kristi L Watterberg; Tracy L Nolen; Carol A Cole; C Michael Cotten; William Oh; Brenda B Poindexter; Kristin M Zaterka-Baxter; Abhik Das; Conra Backstrom Lacy; Ann Marie Scorsone; Michele C Walsh; Edward F Bell; Kathleen A Kennedy; Kurt Schibler; Gregory M Sokol; Matthew M Laughon; Satyanarayana Lakshminrusimha; William E Truog; Meena Garg; Waldemar A Carlo; Abbot R Laptook; Krisa P Van Meurs; David P Carlton; Amanda Graf; Sara B DeMauro; Luc P Brion; Seetha Shankaran; Faruk H Orge; Richard J Olson; Helen Mintz-Hittner; Michael B Yang; Kathryn M Haider; David K Wallace; Mina Chung; Denise Hug; Irena Tsui; Martin S Cogen; John P Donahue; Michael Gaynon; Amy K Hutchinson; Don L Bremer; Graham Quinn; Yu-Guang He; William R Lucas; Timothy W Winter; Stephen D Kicklighter; Kartik Kumar; Patricia R Chess; Tarah T Colaizy; Anna Marie Hibbs; Namasivayam Ambalavanan; Heidi M Harmon; Elisabeth C McGowan; Rosemary D Higgins
Journal:  JAMA       Date:  2018-10-23       Impact factor: 56.272

5.  Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk.

Authors:  Dale L Phelps; Robert M Ward; Rick L Williams; Kristi L Watterberg; Abbot R Laptook; Lisa A Wrage; Tracy L Nolen; Timothy R Fennell; Richard A Ehrenkranz; Brenda B Poindexter; C Michael Cotten; Mikko K Hallman; Ivan D Frantz; Roger G Faix; Kristin M Zaterka-Baxter; Abhik Das; M Bethany Ball; T Michael O'Shea; Conra Backstrom Lacy; Michele C Walsh; Seetha Shankaran; Pablo J Sánchez; Edward F Bell; Rosemary D Higgins
Journal:  Pediatr Res       Date:  2013-09-04       Impact factor: 3.756

6.  Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants.

Authors:  Dale L Phelps; Robert M Ward; Rick L Williams; Tracy L Nolen; Kristi L Watterberg; William Oh; Michael Goedecke; Richard A Ehrenkranz; Timothy Fennell; Brenda B Poindexter; C Michael Cotten; Mikko Hallman; Ivan D Frantz; Roger G Faix; Kristin M Zaterka-Baxter; Abhik Das; M Bethany Ball; Conra Backstrom Lacy; Michele C Walsh; Waldemar A Carlo; Pablo J Sánchez; Edward F Bell; Seetha Shankaran; David P Carlton; Patricia R Chess; Rosemary D Higgins
Journal:  Pediatr Res       Date:  2016-04-13       Impact factor: 3.756

7.  Inositol in preterm infants at risk for or having respiratory distress syndrome.

Authors:  Alexandra Howlett; Arne Ohlsson; Nishad Plakkal
Journal:  Cochrane Database Syst Rev       Date:  2019-07-08

8.  Blood myo-inositol concentrations in preterm and term infants.

Authors:  Luc P Brion; Dale L Phelps; Robert M Ward; Tracy L Nolen; N Mikko K Hallman; Abhik Das; Daniel J Zaccaro; M Bethany Ball; Kristi L Watterberg; Ivan D Frantz; C Michael Cotten; Brenda B Poindexter; William Oh; Ralph A Lugo; Krisa P Van Meurs; T Michael O'Shea; Kristin M Zaterka-Baxter; Rosemary D Higgins
Journal:  J Perinatol       Date:  2020-09-15       Impact factor: 2.521

9.  Inositol Analysis by HPLC and Its Stability in Scavenged Sample Conditions.

Authors:  Robert M Ward; John Sweeley; Ralph A Lugo
Journal:  Med Chem (Los Angeles)       Date:  2015-02

10.  Functional Characterization of Pneumocystis carinii Inositol Transporter 1.

Authors:  Melanie T Cushion; Margaret S Collins; Thomas Sesterhenn; Aleksey Porollo; Anish Kizhakkekkara Vadukoot; Edward J Merino
Journal:  MBio       Date:  2016-12-13       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.